Immunocore Holdings news

Company achieved target enrollment in a pivotal phase III study with potential near-term catalyst (top-line data expected end of 2026). Kimmtrak is showing strong commercial performance with 16% YoY sales growth and established market position as standard of care for uveal melanoma.

The company is actively engaging with investors through multiple high-profile conferences and demonstrating strong commercial traction with KIMMTRAK generating $115.9 million in Q2 2026 revenues with 18% year-over-year growth. The product has received regulatory approvals across major markets (US, EU, Canada, Australia, UK), indicating successful commercialization of their lead therapeutic.

The company reported promising clinical trial results for brenetafusp with strong efficacy metrics (87% 6-month OS rate, 52% DCR) in heavily pretreated patients, including those with PD-1 resistance. The selection of the 160 mcg dose for Phase 3 trials and favorable safety profile support continued development momentum and potential market opportunity.

Strong commercial performance with 14% YoY sales growth for lead product KIMMTRAK, landmark five-year survival data showing doubled OS benefit, solid cash position of $845 million, and expanding pipeline with multiple Phase 3 trials progressing. Net income improved to $13.0 million from $5.0 million YoY. Company is executing on multiple growth opportunities including market expansion and new indications.

Strong clinical data showing KIMMTRAK doubled five-year survival rates (16% vs 8%) in metastatic uveal melanoma with durable benefit across poor prognostic subgroups. This represents the longest follow-up for any T cell engager in solid tumors and solidifies the drug as first-line standard of care, supporting commercial potential and lifecycle management opportunities.